Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>The strength of Abbott's diversified business strategy and execution allowed it to deliver another solid quarter that greatly outperformed expectations despite the challenging environment.</li><li>Since the beginning of last year, EPD has seen double-digit organic sales growth, driven by a consistent cadence of new product releases and great commercial execution.</li><li>Additionally, during the quarter, they changed the leadership at their Sturgis location as well as in their previous organization.</li></ul>

The strength of Abbott's diversified business strategy and execution allowed it to deliver another solid quarter that greatly outperformed expectations despite the challenging environment.Since the beginning of last year, EPD has seen double-digit organic sales growth, driven by a consistent cadence of new product releases and great commercial execution.Additionally, during the quarter, they changed the leadership at their Sturgis location as well as in their previous organization.

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>
<a href="https://www.smartkarma.com/entities/abbott-laboratories" target="_blank" data-smartkarma-citation="entities:11987:1" rel="noopener">Abbott Laboratories (ABT US)</a> reported Q3 results, with total revenue declining 5% y/y, negatively impacted by double-digit decline in nutrition revenue and mid-single-digit decline in diagnostics revenue.  </li>
<li>Global COVID-19 testing-related sales were $1.7 billion in Q3 2022, significantly above expectation but down 11% compared to $1.9 billion in Q3 2021.</li>
<li>Abbott raised its full-year adjusted EPS guidance to $5.17–5.23 (-0.8–0.4% y/y) from $4.90 earlier and around 10% higher from the initial guidance provided in January.</li>
</ul>



Abbott Laboratories (ABT US) reported Q3 results, with total revenue declining 5% y/y, negatively impacted by double-digit decline in nutrition revenue and mid-single-digit decline in diagnostics revenue.  
Global COVID-19 testing-related sales were $1.7 billion in Q3 2022, significantly above expectation but down 11% compared to $1.9 billion in Q3 2021.
Abbott raised its full-year adjusted EPS guidance to $5.17–5.23 (-0.8–0.4% y/y) from $4.90 earlier and around 10% higher from the initial guidance provided in January.


Abbott Laboratories (ABT US): Beat-And-Raise Q3; COVID Testing Sales Dragged; Shares Hit 52-Week Low

<ul>
<li>In July 2022, <a href="https://www.smartkarma.com/entities/sd-biosensor-inc" target="_blank" data-smartkarma-citation="entities:33333:1" rel="noopener">SD Biosensor (137310 KS)</a> in partnership with SJL Partners signed a definitive merger agreement to acquire <a href="https://www.smartkarma.com/entities/meridian-bioscience-inc" target="_blank" data-smartkarma-citation="entities:1559:1" rel="noopener">Meridian Bioscience (VIVO US)</a>  for approximately KRW800 billion (~$1.5 billion).</li>
<li>The acquisition will strengthen SD Biosensos’s IVD platform to navigate the decline in COVID-19 testing demand and accelerate its U.S. market entry.</li>
<li>In September 2021, SD Biosensor acquired ~22% stake in UXN, which aims to launch mini continuous blood glucose meter in domestic market in 2024.</li>
</ul>


In July 2022, SD Biosensor (137310 KS) in partnership with SJL Partners signed a definitive merger agreement to acquire Meridian Bioscience (VIVO US)  for approximately KRW800 billion (~$1.5 billion).
The acquisition will strengthen SD Biosensos’s IVD platform to navigate the decline in COVID-19 testing demand and accelerate its U.S. market entry.
In September 2021, SD Biosensor acquired ~22% stake in UXN, which aims to launch mini continuous blood glucose meter in domestic market in 2024.


SD Biosensor (137310 KS): Aggressively Investing Windfall Gain From COVID; Adding New Growth Engines

<ul>
<li>
<a href="https://www.smartkarma.com/entities/access-bio-inc-kdr" target="_blank" data-smartkarma-citation="entities:5729:1" rel="noopener">Access Bio Inc (950130 KS)</a> has been reporting triple-digit revenue growth since 2020, thanks to massive demand for the COVID-19 tests. The performance continued in this year too.</li>
<li>Going forward, the stellar revenue growth is not expected to be replicated as demand for COVID-19 tests looks uncertain beyond 2022. Revenue from the company’s malaria test is declining.</li>
<li>Access Bio has developed monkeypox tests. However, monkeypox does not seem be a large and attractive market opportunity, which can compensate for the revenue loss from COVID-19 tests.</li>
</ul>



Access Bio Inc (950130 KS) has been reporting triple-digit revenue growth since 2020, thanks to massive demand for the COVID-19 tests. The performance continued in this year too.
Going forward, the stellar revenue growth is not expected to be replicated as demand for COVID-19 tests looks uncertain beyond 2022. Revenue from the company’s malaria test is declining.
Access Bio has developed monkeypox tests. However, monkeypox does not seem be a large and attractive market opportunity, which can compensate for the revenue loss from COVID-19 tests.


Access Bio (950130 KS): COVID-19 Rapid Tests Demand Lose Sheen Sending Share Prices Down to Lows

<ul><li>Abbott Laboratories had a strong financial performance in the recent quarter led by the development of medical, diagnostics, and pharmaceutical devices.</li><li>During this quarter, the company is continuing to strengthen its Medical Device portfolio with new innovative products.</li><li>In this report, we have carried out a fundamental analysis of the historical financial statements of the company.</li></ul>

Abbott Laboratories had a strong financial performance in the recent quarter led by the development of medical, diagnostics, and pharmaceutical devices.During this quarter, the company is continuing to strengthen its Medical Device portfolio with new innovative products.In this report, we have carried out a fundamental analysis of the historical financial statements of the company.

Abbott Laboratories: Capacity Expansion For Diabetes Care & Other Drivers

United States

Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services. The Company's products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Abbott Laboratories (ABT US)

Abbott Laboratories: Major Drivers

The strength of Abbott's diversified business strategy and execution allowed it to deliver another solid quarter that greatly outperformed...

Baptista Research